Skip to content

Efficacy and Safety of Early TIPS (Transjugular Intrahepatic Portosystemic Shunts) in the Management of Cirrhosis With Recurrent Ascites.

Efficacy and Safety of Early TIPS (Transjugular Intrahepatic Portosystemic Shunts) in the Management of Cirrhosis With Recurrent Ascites.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04013074
Enrollment
80
Registered
2019-07-09
Start date
2019-07-09
Completion date
2020-07-31
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhoses

Brief summary

All consecutive patients with cirrhosis of liver who satisfy the criteria will be included and will be evaluated clinically along with all routine investigations and standard medical therapy will be continued among these patients. The patients between 18-60 yrs of age (cirrhosis diagnosed on the basis of clinical, biochemical, fibroscan & imaging.) , with ascites and HVPG (Hepatic Venous Pressure Gradient) \>12, with 2 or more large volume paracentesis in last 3 month . CTP ≥ 7-13 will be considered for the study. At baseline, a complete history of the cause of cirrhosis of liver with clinical and physical examination, a record of demographic profile, standard of care biochemical investigations would be done. In this study patients who satisfy the inclusion and exclusion criteria as mentioned below will be enrolled to receive either standard medical therapy with Large volume paracentesis and albumin infusion or to be randomised to receive TIPS (Transjugular Intrahepatic Portosystemic Shunt). The patients in group A will be given standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required Large Volume Paracentesis (LVP) and albumin infusion and diuretics.

Interventions

Transjugular Intrahepatic Portosystemic Shunt

OTHERStandard Medical Treatment

Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Liver Cirrhotics between 18-60 yrs of age (cirrhosis diagnosed on the basis of clinical, biochemical, fibroscan & imaging) 2. Recurrent ascites (2 or more large volume paracentesis in last 3 month) on maximal tolerated diuretic dose. 3. Diuretic intractable ascites ( developing AKI/ hyponatremia (Na-\<130 , hypo/ hyperkalemia (\<3.5 , \>5.5), who will respond to withdrawal of diuretics 4. HVPG \>12 mm Hg 5. CTP ≥ 7-12 6. Patient is willing and able to comply with all study protocol requirements, including specified follow-up and testing.

Exclusion criteria

1. Hepatic or extra hepatic Malignancy-HCC, PVT 2. MELD (Model for End Stage Liver Disease) \> 18 3. Post TIPS (Transjugular Intrahepatic Portosystemic Shunt), Shunt surgery 4. LVP (Large Volume Paracentesis) \>3/month 5. Acute kidney injury (Sr.Cr\>2mg/dl) 5\) CKD (Chronic Kidney Injury) 6) Previous hepatic encephalopathy 7) Acute on chronic liver failure 8) Active infection 9) Active alcohol intake 10) Left Ventricular systolic dysfunction/ overt CCM 11) PPH (Portopulmonary Hypertension) 12) Pt on mechanical ventilation 13) Patient in ICU/ any acute illness 14) Pregnant lady 15) SBP (Spontaneous bacterial Peritonitis)

Design outcomes

Primary

MeasureTime frame
Transplant free survival in both groups1 year

Secondary

MeasureTime frame
Reduction in HVPG from baseline in both groups6 month
Incidence of Acute Kidney Injury new complications in both groups1 year
Incidence of Spontaneous bacterial Peritonitis in both groups1 year
Overall survival in both groups1 year
Incidence of Bleeding in both groups1 year
Incidence of hyponatremia in both groups1 year
Incidence of Hepatic Encephalopathy in both groups1 year

Countries

India

Contacts

Primary ContactDr Vinay Kumar, MD
drvinaybr@gmail.com01146300000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026